Diabetes is life long affliction that causes a person’s blood sugar level to become too high. With the two main types of diabetes, type 2 is far more common. Around 90% of all adults with diabetes have type 2.
Types
Type 2 is where the body is not creating enough insulin or the body is not reacting correctly to the insulin. This type usually requires the managing of medication, finding the right medication for each person can take time. Also many of the medications have side affects.
Type 1 is when the level of glucose in blood to be too high. This happens when the body isn’t producing enough of the hormone insulin which controls the levels of glucose in blood.
Both types are manageable with the correct advice and medication.
There are articles below that explore the condition in many different ways. Covering new research and evidence.
Afon Technology is pioneering advancements in diabetes care with its innovative device, Glucowear™, which is being developed as the world’s first non-invasive, real-time, continuous blood glucose monitor.
Gwen Carleton, Communication Manager for the World Diabetes Foundation, explores how diabetes still isn’t prioritised by governments and in global development – despite the clear business case for doing so – and hopes that 2018 will mark a turning point
Levels of severe obesity in children aged 10 to 11 years have reached the highest point since records began, according to new figures published today by Public Health England
Dr Eleanor D Kennedy, Research Manager at the Diabetes Research and Wellness Foundation explains why diabetes is a global epidemic and at the same time, a local problem
Yinka Makinde, Programme Director at DigitalHealth.London tells us exactly how digital solutions are having an impact on the self-management of Type 2 diabetes across London in the UK.
Over three and a half million people in the UK are currently living with diabetes, and as that number continues to increase, the role of the diabetes specialist nurse (DSN) is becoming increasingly important. Swansea University Medical School responds to this training gap
The gap in the long process of progressing a novel scientific insight into a new medicine is often called “the valley of death”. Read below to understand how the strategic alliance between University of Oxford and Novo Nordisk is aiming to combat type 2 diabetes by bridging this gap.
Chester Medical school shed light on the link between obesity and diabetes, the challenge facing patients with ‘Diabesity’ and the research contribution of the school in solving this problem
Prof Dr Freimut Schliess, Director of Science & Innovation at Profil Institut für Stoffwechselforschung GmbH explains the important role of innovation when it comes to healthy living and active ageing, including his thoughts on the diabetes paradigm
Professor John Wilding from the University of Liverpool charts priorities for improving patient care in the UK when it comes to the prevalent condition, Type 2 diabetes
Kimberley Hanson, Director of Federal Affairs at Diabetes Canada argues that the country urgently needs a national strategy to tackle the diabetes epidemic
Kristoffer From, CEO of Liva Healthcare and Simon Pickup, UK Managing Director at Liva Healthcare share their thoughts on why obesity is key to tackling the root cause of Type 2 diabetes
